0
0
4/11/23 at 6:26pm
Organization
Multiple Sclerosis News Today
37 words
0
Comments
The benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing MS
You are the first to view
https://multiplesclerosisnewstoday.com/news-posts/2023/04/11/mavenclad-benefits-ms-sustained-up-15-years-after-last-treatment/
Create an account
or login to join the discussion